Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Infographic: Conference Live
Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...
Blog: The Cost of Counterfeits
The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.
Video: Self-pay and Emerging Markets
A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...
News: Therapy Watch HCV expands into 4 additional EU markets
The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...
News: Research Partnership launches new patient report – Living with Ulcerative Colitis
Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...
Summer Intern experience at Research Partnership
We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research
Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations
Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...
Beyond Andrology: Trends in Men’s Health in Emerging Markets
Published in eyeforpharma July 2016 by Rachel Howard
Pharma & life sciences division growth allows Pegasus to fill three new senior positions
Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.
Infographic: HIV Market Snapshot
Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...